CN110731432A - 一种海藻益生元护胃饮料及其制备方法 - Google Patents
一种海藻益生元护胃饮料及其制备方法 Download PDFInfo
- Publication number
- CN110731432A CN110731432A CN201911130140.XA CN201911130140A CN110731432A CN 110731432 A CN110731432 A CN 110731432A CN 201911130140 A CN201911130140 A CN 201911130140A CN 110731432 A CN110731432 A CN 110731432A
- Authority
- CN
- China
- Prior art keywords
- seaweed
- stomach
- parts
- extract
- guar gum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 46
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241001474374 Blennius Species 0.000 title claims description 66
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229920002907 Guar gum Polymers 0.000 claims abstract description 38
- 239000000665 guar gum Substances 0.000 claims abstract description 38
- 235000010417 guar gum Nutrition 0.000 claims abstract description 38
- 229960002154 guar gum Drugs 0.000 claims abstract description 38
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000661 sodium alginate Substances 0.000 claims abstract description 27
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 27
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 27
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 23
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 23
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 23
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 23
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 23
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 23
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 23
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 23
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 23
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 23
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 22
- 235000021552 granulated sugar Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000008234 soft water Substances 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims description 24
- 241001092040 Crataegus Species 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 230000001954 sterilising effect Effects 0.000 claims description 17
- 239000006228 supernatant Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 15
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 230000001502 supplementing effect Effects 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 108090000526 Papain Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 238000005238 degreasing Methods 0.000 claims description 2
- 238000011033 desalting Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 235000019643 salty taste Nutrition 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 239000007974 sodium acetate buffer Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 241000195474 Sargassum Species 0.000 claims 2
- 238000007605 air drying Methods 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 239000012510 hollow fiber Substances 0.000 claims 1
- 238000009928 pasteurization Methods 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 239000004576 sand Substances 0.000 claims 1
- 235000020510 functional beverage Nutrition 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 19
- 201000005917 gastric ulcer Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 229920001282 polysaccharide Polymers 0.000 description 18
- 239000005017 polysaccharide Substances 0.000 description 18
- 150000004804 polysaccharides Chemical class 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 10
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 9
- 108010012715 Superoxide dismutase Proteins 0.000 description 9
- 229940118019 malondialdehyde Drugs 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 102100036698 Golgi reassembly-stacking protein 1 Human genes 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 7
- 210000001156 gastric mucosa Anatomy 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229920000855 Fucoidan Polymers 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 102000005747 Transcription Factor RelA Human genes 0.000 description 3
- 108010031154 Transcription Factor RelA Proteins 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000003170 nutritional factors Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 125000003436 D-mannopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical group 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及功能性饮料技术领域,尤其涉及一种海藻益生元护胃饮料及其制备方法。包括以下质量分数的原料:20‑30份海藻酸钠、13‑25份瓜尔胶提取物、5‑15份海藻提取物、1‑6份瓜尔胶、80‑100份白砂糖、1‑8份柠檬酸、5‑20份浓缩山楂汁及800‑1000份软水。制备中以海藻提取物,瓜尔胶提取物及海藻酸钠为原料,添加浓缩山楂汁,辅以白砂糖、柠檬酸,灌装后经杀菌制成。本发明通过激活抗氧化酶活性、减少脂质过氧化和炎症反应而实现防治酒精性胃溃疡的目的,得到了一种效果好、可大规模流通的海藻益生元护胃饮料。
Description
技术领域
本发明涉及功能性饮料技术领域,尤其涉及一种海藻益生元护胃饮料及其制备方法。
背景技术
酒精性胃溃疡是一种常见的急性胃损伤疾病,经口摄入大量酒精会直接损害胃黏膜上皮细胞,破坏胃黏膜屏障,引起急性胃黏膜充血、糜烂甚至浅表性溃疡。而且随着生活方式转变,酒精引起的相关疾病发生率逐年上升,流行病学调查发现其发病率达到10%-12%,饮酒人群发生胃肠道疾病的概率远高于非饮酒人群。酒精性胃溃疡的病理过程一般涉及炎症反应、氧化应激和细胞凋亡等几个方面。有研究显示,较高浓度的乙醇可在摄食后30分钟至1小时内导致体内出现胃溃疡。治疗胃溃疡的药物主要包括H2受体拮抗剂、胃酸抑制剂、质子泵抑制剂等,发挥作用的同时也有严重的副作用,比如勃起功能障碍、心律失常、雌激素失调、不孕不育等。因此,寻找安全有效的防治酒精性胃溃疡的功能性食品具有重要意义。
发明内容
本发明要解决的技术问题是治疗胃溃疡的药物主要包括H2受体拮抗剂、胃酸抑制剂、质子泵抑制剂等,发挥作用的同时也有严重的副作用,需要寻求一种安全有效的防治酒精性胃溃疡的功能性食品。
为解决上述问题,本发明通过将海藻酸钠、海藻提取物与瓜尔胶提取物作为主要成分,辅助其他成分,通过激活抗氧化酶活性、减少脂质过氧化和炎症反应而实现防治酒精性胃溃疡的目的,得到了一种效果好、可大规模流通的海藻益生元护胃饮料。
为达到上述目的,本发明通过以下技术方案实现:一种海藻益生元护胃饮料,包括以下质量分数的原料:20-30份海藻酸钠、13-25份瓜尔胶提取物、5-15份海藻提取物(2-20ku)、1-6份瓜尔胶、80-100份白砂糖、1-8份柠檬酸、5-20份浓缩山楂汁及800-1000份软水。
其中,海藻酸钠:本身的溶解性、粘性及安全性,使其在该技术中作为稳定剂及载体:海藻酸钠含有大量的-COO-,在水溶液中表现出聚阴离子行为,具有一定的黏附性,可以作为海藻提取物的载体。在酸性条件下,-COO-转变成-COOH,电离度降低,海藻酸钠的亲水性降低,分子链收缩,pH增加时,-COOH不断地解离,海藻酸钠的亲水性增加,分子链从而伸展。此外,海藻酸钠具有凝胶性,将海藻提取物及瓜尔胶提取物包裹其中,减少与阳离子等的接触,避免海藻提取物及瓜尔胶提取物失活。
瓜尔胶提取物:采用β-甘露聚糖酶水解瓜尔胶所得,主要成分为瓜尔胶寡糖,有研究表明其能显著增进人体肠道内以双歧杆菌为代表的有益菌的增殖,且具有减少肠道病原菌、增强免疫、提高肠黏膜功能等多种特性,从而起到保护肠胃健康的作用。
海藻提取物:大量乙醇进入胃体后,会引起胃黏膜损伤,其特征为黏膜水肿、瘀斑出血、上皮细胞损伤、炎症细胞浸润等。海藻提取物中的岩藻聚糖是一种富含硫酸基团的酸性多糖,广泛的存在于褐藻(如海带)、海参等海产品中,尤其是低分子量和中分子量的岩藻聚糖对抗氧化酶具有保护作用,从而抑制脂质过氧化,提升PEG-2和胃部NO含量,从而具有预防和治疗胃溃疡的作用。其提取方法如下:
将海藻洗去泥沙,剪成小块、粉碎,于4℃丙酮中浸泡脱脂24h,室温下晾干。称取100g海藻干粉进行酶解,对应1g干物加入30ml0.1mol/L乙酸钠缓冲液(pH6.0)、100mg木瓜蛋白酶、5mmol/l EDTA溶液和5mmol/L半胱氨酸溶液,于60℃水浴下搅拌反应24h之后,反应混合物离心(4000r/min,15min,20℃),取上清液。向上清液中加入1.6ml的10%的CPC溶液,于室温下放置24h后,离心(4500r/min,15min,20℃),弃去上清液,沉淀溶解于15ml3mol/LNaCl:乙醇(100:15v/v)溶液中,再加入30ml 80%和95%乙醇洗2到3次,至无咸味为止,最后将沉淀于60℃干燥2h,蒸馏水溶解,用截留分子量6000Da的中空纤维膜超滤脱盐、浓缩、冻干,得到海藻提取物。其中,木瓜蛋白酶的作用是酶解破坏蛋白链,以季铵盐作为沉淀剂将多糖分离出来,季铵盐是一种表面活性剂,可与带负电荷的多糖产生不溶物,由于提取过程中蛋白链与糖链之间的糖肽键难以断裂,所以采用木瓜蛋白酶酶解配合CPC沉淀的方式得到的海藻多糖,相比于传统碱结合乙醇沉淀的工艺,纯度高,条件温和,不影响多糖原始结构,得到的多糖主要由葡萄糖醛酸、氨基半乳糖、半乳糖和岩藻聚糖组成,而岩藻聚糖是其中比例最高的。
瓜尔胶:一种非离子多糖,以聚甘露糖为分子主链,D-吡喃甘露糖单元之间以β(1-4)苷键连接。而D-吡喃半乳糖则以α(1-6)键连接在聚甘露糖主链上,容易水化,氢键结合活性高,作为天然的增稠剂,达到一个口感上的升级。
山楂浓缩汁,酸甘,微温。所含的解脂酶能促进脂肪类食物的消化,进而减少脂质的过氧化,避免损害其他细胞结构造成的机体功能障碍;同时可以增加胃内酶素,而胃内酶素主要是消化酶,同时包含一些纤维素,对胃粘膜起到滋养及促进胃肠道蠕动作用,辅助加快酒精代谢、增强胃黏膜对酒精的防御能力,从而辅助防治酒精性胃溃疡。
白砂糖和柠檬酸主要起到调节口味的作用,其次在整个配伍体系中可提供糖原、调节pH,保证体系稳定。
水作为溶剂,其添加量需严格控制,保证各组分的浓度稳定,从而控制护胃效果。
进一步的,所述软水为经软化处理只含有少量的可溶性镁盐和钙盐的天然水,可以保证口感;另外,去除了软水去除了金属离子,特别是镁离子、钙离子,能够避免在凝胶过程中形成沉淀,饮料的稳定性更高。
一种上述海藻益生元护胃饮料的制备方法,将原料顺序溶解、混合后分离、杀菌,得到成品;其中原料的溶解顺序为:溶解海藻酸钠,将瓜尔胶提取物、海藻提取物、白砂糖、瓜尔胶加入海藻酸钠溶解液中得到混合液A,溶解柠檬酸和浓缩山楂汁得到混合液B,将混合液B加入混合液A中,补充软水。具体包括以下步骤:
(1)按比例称取除软水外的各原料;
(2)取部分软化水加热,然后边搅拌边加入海藻酸钠,完全溶解后,静置备用;
(3)将瓜尔胶提取物、海藻提取物、白砂糖、瓜尔胶加入步骤(2)的混合物中;
先溶解海藻酸钠使海藻酸钠充分水合,后溶解瓜尔胶提取物、海藻提取物、白砂糖、瓜尔胶这些相对溶解性好的原辅料。若更换溶解顺序,其他物料会影响海藻酸钠的溶解性和水合效果,如水中的糖会降低海藻酸钠的水合速率,延长溶料时间。而先溶解海藻酸钠,在海藻酸钠凝胶后能够对瓜尔胶提取物、海藻提取物、白砂糖、瓜尔胶分子形成包裹,最终得到的溶液体系也更加稳定,口感更加厚实温和。
(4)溶解柠檬酸和浓缩山楂汁;
(5)将步骤(4)中的溶液加入步骤(3)中,再用软化水补充至软化水分量;由于(4)中的柠檬酸与浓缩山楂汁直接参与混料,会使体系局部变酸,局部pH急剧下降,体系不稳定。且柠檬酸在热水40℃以上溶解会出现白片沉淀,需在冷水下溶解,溶解好的柠檬酸溶液正好稀释粘度大粘壁强的浓缩山楂汁,二者混合均匀后缓慢加入到(3)中,避免因局部pH值急剧下降造成的溶液不稳定。
(6)将步骤(5)的溶液均质;
(7)将步骤(6)均质后的料液进行离心或板框过滤,获取上清液,除去浓缩山楂汁中可能存在的山楂渣子,保证体系稳定;
(8)杀菌得到成品。
进一步的,步骤(2)的加热温度为80-85℃,搅拌时间为15-20min,静置时间为1h。
进一步的,步骤(4)溶解柠檬酸和浓缩山楂汁的水温为0-30℃。
进一步的,步骤(6)的均质条件为100-200bar。
进一步的,步骤(7)的离心条件为4500r/min离心10min;或采用无菌处理200目板框过滤。
进一步的,步骤(8)的杀菌为将半品溶液灌装成瓶;在121℃条件下反压杀菌15min,或在压力102KPa、温度121℃±2℃、保持20min-30min的条件下进行高压蒸汽灭菌。
进一步的,灌装前将步骤(7)得到的上清液进行巴氏杀菌,杀菌条件为95℃下杀菌5min;或者对上清液进行高温瞬时杀菌,杀菌条件为100-130℃下杀菌3-20s。利用板式换热器设备进行巴氏杀菌可以保留营养成分及口感风味;灌装后进行灭菌保证产品的商业无菌。
本发明的有益效果在于:
(1)本发明护胃饮料具有其特有的营养因子(海藻酸钠、瓜尔胶提取物、海藻提取物、瓜尔胶),各营养因子协同作用,比单一阴阳因子的作用总和更有效。
(2)本发明的制备方法工艺简单、条件温和,最大程度上保持营养因子的活性,提高了产品的使用安全性。
(3)本发明制备得到的护胃饮料为纯天然提取物,口味清新,口感好,稳定性佳,易于携带,适合大规模的生产推广,更是亚健康状态下良好的饮料选择。
附图说明
图1:本发明各组胃腺部(部分)解剖镜结果(放大倍数3x,n=5);
图2:海藻饮料对小鼠血清ALT、AST影响(n=5);
图3:本发明海藻饮料对小鼠血清MDA的影响;
图4:本发明海藻饮料对小鼠血清SOD的影响(n=5);
图5:本发明海藻饮料对小鼠血清TNF-α、IL-6的影响(n=5);
图6:胃组织中NF-κB P65、p-NF-κB P65蛋白表达对比图;
图中,数据采用means±SD表示。##P<0.01、#P<0.01与Sham组比较;**P<0.01、*P<0.05与OVX组比较;
a正常组;b模型组;c清幽乐低;d清幽乐高;e海藻饮料低;f海藻饮料高。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述。显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
一种海藻益生元护胃饮料,包括以下质量的原料:20g海藻酸钠、13g瓜尔胶提取物、5g海藻提取物、1g瓜尔胶、80g白砂糖、1g柠檬酸、5g浓缩山楂汁及1000ml软水。
一种上述海藻益生元护胃饮料的制备方法,包括以下步骤:
(1)按比例称取除软水外的各原料;
(2)取部分纯水加热,然后边搅拌边加入海藻酸钠,完全溶解后,静置备用;其中,加热温度为85℃,搅拌时间为15min,静置时间为1h;
(3)将瓜尔胶提取物、海藻提取物、白砂糖、瓜尔胶加入步骤(2)的混合物中;
(4)溶解柠檬酸和浓缩山楂汁;
(5)将步骤(4)中的溶液加入步骤(3)中,再用软化水补充至软化水分量;
(6)将步骤(5)的溶液均质;均质条件为200bar;
(7)将步骤(6)均质后的料液进行离心,获取上清液;离心条件为4500r/min离心10min;
(8)将步骤(7)得到的上清液进行巴氏杀菌,杀菌条件为95℃下杀菌5min;将溶液灌装成瓶,在121℃条件下反压杀菌15min。
实施例2:
步骤(8)为将步骤(7)得到的上清液进行高温瞬时杀菌,杀菌条件为105±1℃、持续15s。
其余均与实施例1相同。
实施例3:
步骤(8)为将步骤(7)得到的上清液进行高温瞬时杀菌,杀菌条件为124±2℃、持续4s。
其余均与实施例1相同。
实施例4:
步骤(4)溶解柠檬酸和浓缩山楂汁的水温为10℃。
其余均与实施例1-3之一相同。
实施例5:
步骤(7)采用无菌处理200目板框过滤。
其余均与实施例1-4之一相同。
实施例6:
步骤(9)为在压力102KPa、温度121℃±2℃、保持15min的条件下进行高压蒸汽灭菌。
其余均与实施例1-5之一相同。
实施例7:
一种海藻益生元护胃饮料,包括以下质量的原料:25g海藻酸钠、20g瓜尔胶提取物、10g海藻提取物、3g瓜尔胶、80g白砂糖、6g柠檬酸、15g浓缩山楂汁及1000ml软水。
其余均与实施例1-6之一相同。
实施例8:
一种海藻益生元护胃饮料,包括以下质量的原料:30g海藻酸钠、20g瓜尔胶提取物、15g海藻提取物、5g瓜尔胶、90g白砂糖、7g柠檬酸、20g浓缩山楂汁及900ml软水。
其余均与实施例1-6之一相同。
实施例9:
一种海藻益生元护胃饮料,包括以下质量的原料:23g海藻酸钠、20g瓜尔胶提取物、12g海藻提取物、4g瓜尔胶、85g白砂糖、3g柠檬酸、18g浓缩山楂汁及1000ml软水。
其余均与实施例1-6之一相同。
实施例10:
一种海藻益生元护胃饮料,包括以下质量的原料:30g海藻酸钠、25g瓜尔胶提取物、15g海藻提取物、6g瓜尔胶、100g白砂糖、8g柠檬酸、20g浓缩山楂汁及1000ml软水。
其余均与实施例1-6之一相同。
结果验证:
1.实验材料
1.1材料和动物
清幽乐饮料,购于青岛明月海藻集团有限公司。
健康ICR小鼠,雄性,8周龄,体重(18.0±2.0g),SPF级,购于济南朋悦实验动物繁育有限公司,许可证号:SCXK(鲁)2014-0007。
1.2主要试剂和仪器
谷草转氨酶(AST)、谷丙转氨酶(ALT)、丙二醛(MDA)、超氧化物歧化酶(SOD)、TNF-α、IL-6试剂盒(南京建成生物工程研究所),β-actin、NF-κB、p-NF-κB抗体(Cell Signaling公司)。
SZ61型解剖镜(Olympus)、Model680型酶标仪(美国Bio–Rad公司),DYCP-40型半干转膜仪、Tanon-520型全自动化学发光成像分析系统(上海天能科技有限公司)。
2.实验方法
2.1饮料的制备
参照上述实施例1-10的方案制备饮料。清幽乐饮料中褐藻胶含量为26.3mg/kg,海藻提取物含量为9.0mg/kg。
2.2动物分组和建模
ICR小鼠随机分成正常对照组(N),模型对照组(M)和清幽乐低(清幽乐低,8.8mg/kg)、清幽乐高(清幽乐高,26.3mg/kg)剂量组,海藻饮料低(实施例1),7.2mg/kg)、海藻饮料高(实施例8),21.5mg/kg)剂量组,每组5只。清幽乐和海藻饮料组灌胃相应剂量的受试物,正常组和模型组灌胃生理盐水,灌胃体积均为10mL/kg.bw,连续灌胃14d。实验期间大鼠自由饮水和进食普通饲料。
取材前一天禁食22h,禁水4h,进行末次灌胃。末次灌胃1h后模型组、清幽乐和海藻饮料各剂量组灌胃10mL/kg.bw 85%乙醇造模,正常组灌胃生理盐水。造模1h过后,摘眼球取血,分离血清备用。摘取胃部,沿胃大弯剪开,部分置于10%中性甲醛固定,待镜鉴观察。另一部分生理盐水洗净,立即置于液氮保存备用。
2.3胃溃疡出血状况和溃疡指数的测定
解剖镜观察胃组织拍照,用Olympus Image Pro Plus软件统计胃溃疡出血面积和胃腺部总面积,参照下面的方法计算溃疡指数、溃疡抑制率。
2.4血清因子水平的测定
参照试剂盒所述方法进行测定血清AST、ALT、MDA、SOD、TNF-α、IL-6。
2.5Western blot
将胃组织置于RIPA组织裂解液中充分裂解,收集总蛋白。总蛋白经SDS-PAGE电泳后转印至PVDF膜,室温封闭3h,分别与NF-KB P65、p-NF-KB P65一抗4℃孵育过夜后漂洗,与二抗反应,在ECL超敏发光液下显色,发光系统获取蛋白条带。蛋白相对表达量以目的蛋白表达量/β-actin蛋白表达量来表示。
2.6统计学分析
数据均用Means±SD表示,用SPSS 17.0软件进行ANOVA单因素方差分析,采用LSD法进行组间比较,P<0.05为具有统计学差异。
3.结果分析
3.1海带多糖饮料对小鼠胃溃疡出血及溃疡指数的影响
由图1和表1可看出,与正常组相比,模型组出血情况严重,出血点达到(82.6±30.2)/(处·只),溃疡指数显著增加(P<0.01)。经清幽乐和海藻饮料低高剂量干预后,均显著减少了小鼠的出血情况和溃疡指数(P<0.01),经计算胃溃疡抑制率分别为35.17%、61.78%、42.6%、76.58%。海藻饮料降低胃溃疡指数和提高胃溃疡抑制率,其效果优于清幽乐,并均呈现一定的量效关系。
表1各组胃溃疡出血点、指数、抑制率统计(n=5)
Table 1 Effect ofeach group on anhydrous alcohol-induced gastricmucosal injury in mice(n=5)
注:数据采用means±SD表示。##P<0.01、#P<0.01与Sham组比较;**P<0.01、*P<0.05与OVX组比较。
3.2血清ALT、AST含量
从图2可知,模型组小鼠的ALT、AST均极显著高于正常组(P<0.01)。分别摄入海藻饮料和清幽乐饮料后,小鼠ALT、AST水平均显著下降(P<0.05),与模型组相比,海藻饮料低剂量分别下降15.70%、23.82%,高剂量则下降37.49%、41.57%,比对应剂量的清幽乐效果好。提示海藻饮料和清幽乐饮料均呈量效关系降低模型小鼠的ALT、AST。
3.3血清MDA、SOD水平的测定
从图3和图4可知,与正常组相比,模型组小鼠的MDA显著高于正常组、SOD显著低于正常组(P<0.01)。摄入清幽乐饮料后,低高剂量组小鼠MDA水平比模型组分别显著下降17.67%、42.76%(P<0.01),SOD水平显著增加79.19%、90.22%(P<0.01)。摄入海藻饮料后,低高剂量组MDA水平显著下降26.69%、31.89%(P<0.01),SOD水平则增加了87.67%、102.94%(P<0.01)。
3.4血清TNF-α、IL-6水平
从图5可知,与正常组相比,模型组小鼠的TNF-α、IL-6均极显著增高(P<0.01)。清幽乐和海藻饮料组的TNF-α和IL-6水平较模型组均显著下降(P<0.05),其中,海藻饮料低剂量分别下降33.76%、26.69%,高剂量则下降49.86%、31.89%,清幽乐对应低高剂量下降幅度小于海藻饮料。
3.5胃组织NF-κB P65、p-NF-κB P65蛋白水平的测定
由图6可见,模型组小鼠的NF-κB P65和p-NF-κB P65蛋白表达水平显著高于正常组(P<0.01)。分别摄入清幽乐和海藻饮料后,与模型组相比两种蛋白表达水平下调。提示海藻饮料能够呈量效关系降低NF-κB P65和p-NF-κB P65的表达量,效果优于清幽乐。
氧化应激是酒精性胃溃疡的重要发病机制。过量乙醇在体内不能及时氧化代谢,会诱导超氧化物、羟基阴离子和过氧化氢等活性氧的产生,引起脂质过氧化反应,损害其他细胞结构,造成机体功能障碍。MDA是细胞脂质过氧化的终产物之一,会使蛋白、核酸等分子变性沉积,造成细胞损伤。正常人体内拥有大量的自由基清除酶系,SOD就是其中一种重要的酶。在本实验中,海藻饮料和清幽乐干预后,能够显著的降低MDA水平、增加了SOD的表达,ALT、AST恢复到正常水平,从而减少了对肝脏的损伤,提示海藻饮料可以通过调节机体氧化应激水平来改善胃溃疡。
多项研究表明,TNF-α、IL-6等炎症因子在急性胃溃疡起着重要的调节作用,TNF-α能有效刺激中性粒细胞向胃粘膜组织浸润,IL-6协同触发其他促炎细胞因子的进一步表达。NF-κB信号通路是调控炎症的重要通路,介导TNF-α、IL-6等促炎因子的分泌,进一步加剧炎症反应。本发明实验结果表明海藻饮料和清幽乐,可能通过调节NF-Kb信号通路,降低模型小鼠TNF-α、IL-6的表达水平。
综上所述,海藻饮料对急性胃溃疡有明显的保护作用,优于添加了3%海带浓缩粉的清幽乐,其配方和配比更加科学,护胃效果更好。
最后需要说明,以上实施例虽然描述了本发明的具体实施方式,但是并非限制本发明;本领域的技术人员应当理解,这些仅是举例说明,本发明的保护范围是由所附权利要求书所限定的。而一切进行修改或等同替换,其均应包含在本发明的保护范围中。
Claims (10)
1.一种海藻益生元护胃饮料,其特征在于包括以下质量分数的原辅料:20-30份海藻酸钠、13-25份瓜尔胶提取物、5-15份海藻提取物、1-6份瓜尔胶、80-100份白砂糖、1-8份柠檬酸、5-20份浓缩山楂汁及800-1000份软水。
2.如权利要求1所述的海藻益生元护胃饮料,其特征在于其中海藻提取物的提取方法为:将海藻洗去泥沙,剪成小块、粉碎,于4℃丙酮中浸泡脱脂24h,室温下晾干。称取100g海藻干粉进行酶解,对应1g干物加入30ml0.1mol/L乙酸钠缓冲液、100mg木瓜蛋白酶、5mmol/lEDTA溶液和5mmol/L半胱氨酸溶液,于60℃水浴下搅拌反应24h之后,反应混合物离心,取上清液;向上清液中加入1.6ml的10%的CPC溶液,于室温下放置24h后,离心,弃去上清液,沉淀溶解于15ml 3mol/LNaCl:乙醇(100:15v/v)溶液中,再加入30ml 80%和95%乙醇洗2到3次,至无咸味为止,最后将沉淀于60℃干燥2h,蒸馏水溶解,用截留分子量6000Da的中空纤维膜超滤脱盐、浓缩、冻干,得到海藻提取物。
3.一种权利要求1中所述海藻益生元护胃饮料的制备方法,其特征在于:将原料顺序溶解、混合后分离、杀菌,得到成品;其中原料的溶解顺序为:溶解海藻酸钠,将瓜尔胶提取物、海藻提取物、白砂糖、瓜尔胶加入海藻酸钠溶解液中得到混合液A,溶解柠檬酸和浓缩山楂汁得到混合液B,将混合液B加入混合液A中,补充软水。
4.如权利要求3所述的海藻益生元护胃饮料的制备方法,其特征在于包括以下步骤:
(1)按比例称取除软水外的各原料;
(2)取部分纯水加热,然后边搅拌边加入海藻酸钠,完全溶解后,静置备用;
(3)将瓜尔胶提取物、海藻提取物、白砂糖、瓜尔胶加入步骤(2)的混合物中;
(4)溶解柠檬酸和浓缩山楂汁;
(5)将步骤(4)中的溶液加入步骤(3)中,再用软化水补充至软化水分量;
(6)将步骤(5)的溶液均质;
(7)将步骤(6)均质后的料液进行离心或板框过滤,获取上清液;
(8)杀菌得到成品。
5.如权利要求4所述的海藻益生元护胃饮料的制备方法,其特征在于:步骤(2)的加热温度为80-85℃,搅拌时间为15-20min,静置时间为1h。
6.如权利要求4所述的海藻益生元护胃饮料的制备方法,其特征在于:步骤(4)溶解柠檬酸和浓缩山楂汁的水温为0-30℃。
7.如权利要求4所述的海藻益生元护胃饮料的制备方法,其特征在于:步骤(6)的均质条件为100-200bar。
8.如权利要求4所述的海藻益生元护胃饮料的制备方法,其特征在于:步骤(7)的离心条件为4500r/min离心10min;或采用无菌处理200目板框过滤。
9.如权利要求4所述的海藻益生元护胃饮料的制备方法,其特征在于:步骤(8)的杀菌为将溶液灌装成瓶;在121℃条件下反压杀菌15min,或在压力102KPa、温度121℃±2℃、保持20min-30min的条件下进行高压蒸汽灭菌。
10.如权利要求9所述的海藻益生元护胃饮料的制备方法,其特征在于:灌装前将步骤(7)得到的上清液进行巴氏杀菌,杀菌条件为95℃下杀菌5min;或者对上清液进行高温瞬时杀菌,杀菌条件为100-130℃下杀菌3-20s。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911130140.XA CN110731432A (zh) | 2019-11-18 | 2019-11-18 | 一种海藻益生元护胃饮料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911130140.XA CN110731432A (zh) | 2019-11-18 | 2019-11-18 | 一种海藻益生元护胃饮料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110731432A true CN110731432A (zh) | 2020-01-31 |
Family
ID=69273122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911130140.XA Pending CN110731432A (zh) | 2019-11-18 | 2019-11-18 | 一种海藻益生元护胃饮料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110731432A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0645143A1 (en) * | 1993-09-24 | 1995-03-29 | Kabushiki Kaisha Yakult Honsha | Antiulcer agent and adhesion inhibitor for helicobacter pyroli |
US20100168056A1 (en) * | 2005-10-24 | 2010-07-01 | Troup John P | Dietary fiber formulation and method of administration |
CN101991598A (zh) * | 2010-12-06 | 2011-03-30 | 吉林省辉南长龙生化药业股份有限公司 | 褐藻多糖硫酸酯在制备治疗胃肠疾病药物中的用途 |
CN108813591A (zh) * | 2018-06-05 | 2018-11-16 | 青岛明月海藻生物科技有限公司 | 一种海藻酵素冻及其制备方法 |
CN108904524A (zh) * | 2018-06-22 | 2018-11-30 | 中国海洋大学 | 低分子量岩藻聚糖硫酸酯在预防和治疗肠炎中的应用 |
CN113545474A (zh) * | 2020-04-21 | 2021-10-26 | 王利华 | 含有增稠作用组份的固态成型食品及用途 |
-
2019
- 2019-11-18 CN CN201911130140.XA patent/CN110731432A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0645143A1 (en) * | 1993-09-24 | 1995-03-29 | Kabushiki Kaisha Yakult Honsha | Antiulcer agent and adhesion inhibitor for helicobacter pyroli |
CN1108572A (zh) * | 1993-09-24 | 1995-09-20 | 株式会社雅库路特本社 | 抗溃疡剂和幽门螺旋菌粘连抑制剂 |
US20100168056A1 (en) * | 2005-10-24 | 2010-07-01 | Troup John P | Dietary fiber formulation and method of administration |
CN101991598A (zh) * | 2010-12-06 | 2011-03-30 | 吉林省辉南长龙生化药业股份有限公司 | 褐藻多糖硫酸酯在制备治疗胃肠疾病药物中的用途 |
CN108813591A (zh) * | 2018-06-05 | 2018-11-16 | 青岛明月海藻生物科技有限公司 | 一种海藻酵素冻及其制备方法 |
CN108904524A (zh) * | 2018-06-22 | 2018-11-30 | 中国海洋大学 | 低分子量岩藻聚糖硫酸酯在预防和治疗肠炎中的应用 |
CN113545474A (zh) * | 2020-04-21 | 2021-10-26 | 王利华 | 含有增稠作用组份的固态成型食品及用途 |
Non-Patent Citations (6)
Title |
---|
刘文, 中国中医药出版社 * |
孔俊豪等: "瓜尔胶及其衍生物最新研究进展", 《食品研究与开发》 * |
孙华吉译: "水解瓜尔豆胶——新一代水溶性膳食纤维", 《中国食品添加剂》 * |
张学伟: "《蔬果汁养生大全》", 31 July 2015, 中医古籍出版社 * |
王中旺: "《中华面文化大典》", 31 January 2005, 经济日报出版社 * |
秦益民: "《海洋功能性食品配料:褐藻多糖的功能和营养》", 31 August 2019, 中国轻工业出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1096867C (zh) | 抗溃疡剂和幽门螺旋菌粘连抑制剂 | |
US9907827B2 (en) | Prebiotic mixture | |
CN104273629A (zh) | 一种蜂蜜醋饮料 | |
JP6285497B2 (ja) | 鶏冠抽出物含有経口組成物及び鶏冠抽出物の香味に由来する摂取困難性の改善方法 | |
JP5688356B2 (ja) | ストレス緩和剤 | |
KR100770775B1 (ko) | 면역증강을 위한 기능성 음료 및 그 제조방법 | |
CN103977021A (zh) | 低聚古罗糖醛酸盐在制备防治肝损伤和各种肝炎、肝纤维化或肝硬化药物中的应用 | |
CN103372189A (zh) | 一种防治禽腺胃炎的复方中药提取物制剂及其制备方法 | |
CN114712440A (zh) | 一种舒缓老年皮肤瘙痒症的傣药组合物及其制剂与应用 | |
CN102613634B (zh) | 一种怀山药固元粥饮品 | |
JP2001231497A (ja) | 機能性食品 | |
CN110731432A (zh) | 一种海藻益生元护胃饮料及其制备方法 | |
CN103007043A (zh) | 一种治疗禽畜呼吸道感染的组合中药 | |
JP2003146887A (ja) | Nk細胞活性化作用を有する製剤および飲食品 | |
CN106924581A (zh) | 一种治疗腹痛的药酒及其制备方法 | |
CN102599586A (zh) | 一种怀山药益元八珍饮品及其制作工艺 | |
CN113303472A (zh) | 一种利用赤苍藤生产的功能饮料及其制备工艺 | |
JP2022550457A (ja) | 肥満の処置又は防止及び体重管理の方法 | |
CN110859912A (zh) | 一种用于前列腺炎的中药组合物及其制备方法和应用 | |
CN110679797A (zh) | 一种富含魔芋寡糖的瘦身饮料及其制备方法 | |
CN110496148A (zh) | 一种治疗妊娠高血压的杜仲提取物组合物及其应用 | |
CN110755604A (zh) | 一种防治家禽腺肌胃炎的药物组合物及其应用 | |
CN109055140B (zh) | 一种健脑护肝露酒及其制备方法 | |
CN107184690B (zh) | 具有抗炎作用的鸡矢藤-葫芦茶组合物及其制备方法和应用 | |
CN103750330B (zh) | 一种含有牛骨髓粉的口服组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200131 |
|
RJ01 | Rejection of invention patent application after publication |